Apogee Therapeutics, Inc. (APGE) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Waltham, MA, 美国. 现任CEO为 Michael Thomas Henderson.
APGE 拥有 IPO日期为 2023-07-14, 196 名全职员工, 在 NASDAQ Global Market, 市值为 $4.95B.
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
